Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a valuable class of drugs in the management of type 2 diabetes mellitus. These agents simulate the actions of naturally occurring GLP-1, stimulating insulin secretion and reducing glucagon release. Recent investigations have yielded a extensive range of novel GLP-1 receptor agonists

GLP-1 receptor agonists are emerging as a groundbreaking method in the management of diabetes. These innovative medications replicate the actions of naturally occurring glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels. By stimulating GLP-1 receptors, these drugs increase insulin release from the